Most Viewed Articles
Articles | Fulltext downloads | PDF downloads | Total downloads |
---|---|---|---|
Short CommunicationDriver mutations in oncogenesisFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_26_2020 |
35,674 | 4,023 | 39,697 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 1, January-April DOI: 10.25259/IJMIO_30_2020 |
31,369 | 3,089 | 34,458 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2023 |
28,394 | 2,613 | 31,007 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2023 |
26,878 | 2,477 | 29,355 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_15_2023 |
26,686 | 2,472 | 29,158 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_16_2023 |
24,203 | 2,544 | 26,747 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_17_2023 |
22,802 | 1,846 | 24,648 |
EditorialCrucial crossroads: Making the right choice for first-line therapy in advanced urothelial cancerFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_2_2024 |
17,933 | 2,974 | 20,907 |
Review ArticleUse of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective articleFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_3_2024 |
18,055 | 2,706 | 20,761 |
Original ArticleSpectrum of lymphomas in IndiaFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2023 |
17,976 | 2,054 | 20,030 |
Review ArticleHigh-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspectiveFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_1_2024 |
16,695 | 2,437 | 19,132 |
NewsEditorial board tribute to Dr. Amit VermaFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December |
16,104 | 3,020 | 19,124 |
Review ArticleUnderstanding immunotherapy and CAR-T-cells: A narrative reviewFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2023 |
16,714 | 2,209 | 18,923 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_8_2022 |
13,707 | 5,105 | 18,812 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_5_2022 |
12,816 | 5,832 | 18,648 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2023 |
15,133 | 2,437 | 17,570 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_1_2022 |
12,444 | 4,506 | 16,950 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_16_2021 |
14,423 | 2,440 | 16,863 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_29_2022 |
14,423 | 2,343 | 16,766 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_13_2021 |
14,236 | 2,322 | 16,558 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_21_2019 |
12,748 | 3,733 | 16,481 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2022 |
14,843 | 1,549 | 16,392 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 2, May-August DOI: 10.25259/IJMIO_27_2022 |
15,106 | 1,193 | 16,299 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_2_2022 |
11,501 | 4,406 | 15,907 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_26_2021 |
11,037 | 4,757 | 15,794 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 3, September-December DOI: 10.25259/IJMIO_14_2022 |
10,887 | 4,560 | 15,447 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_22_2021 |
12,474 | 2,549 | 15,023 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_3_2022 |
9,455 | 5,438 | 14,893 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text![]() ![]() ![]() Year: 2023, Volume: 8, Issue: 3, September-December DOI: 10.25259/IJMIO_11_2023 |
12,936 | 1,736 | 14,672 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_36_2020 |
10,987 | 3,567 | 14,554 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_6_2021 |
11,870 | 2,675 | 14,545 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_15_2020 |
9,874 | 4,633 | 14,507 |
Review ArticleAntibody-drug conjugate review in breast cancer: A targeted approachFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 3, September-December DOI: 10.25259/IJMIO_30_2024 |
5,896 | 8,598 | 14,494 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_12_2021 |
11,289 | 2,880 | 14,169 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_2_2021 |
10,310 | 3,802 | 14,112 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_2_2019 |
8,825 | 5,179 | 14,004 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_11_2022 |
11,112 | 2,842 | 13,954 |
EditorialNanobytesFull text![]() ![]() ![]() Year: 2019, Volume: 4, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2019 |
6,667 | 7,175 | 13,842 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, May-August DOI: 10.25259/IJMIO_28_2020 |
10,252 | 3,513 | 13,765 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2021 |
11,312 | 2,385 | 13,697 |
Review ArticleEmerging strategies in cancer immunotherapy: Expanding horizons and future perspectivesFull text![]() ![]() ![]() Year: 2024, Volume: 9, Issue: 3, September-December DOI: 10.25259/IJMIO_24_2024 |
6,189 | 7,485 | 13,674 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_10_2021 |
10,770 | 2,768 | 13,538 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_20_2021 |
11,373 | 2,137 | 13,510 |
ErratumErratum for manuscript “Muir Torre Syndrome – An Indian Case report” (IJMIO_5_2020)Full text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 2, October DOI: 10.25259/IJMIO_05_2020_ER |
11,631 | 1,652 | 13,283 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 2, May-August DOI: 10.25259/IJMIO_19_2019 |
9,021 | 4,261 | 13,282 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text![]() ![]() ![]() Year: 2021, Volume: 6, Issue: 3, September-December DOI: 10.25259/IJMIO_7_2021 |
10,329 | 2,790 | 13,119 |
Review ArticleResistance to poly ADP-ribose polymerase inhibitors and its clinical implicationsFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_12_2022 |
8,120 | 4,845 | 12,965 |
Review ArticleCell biological basis of tumor relapse and recurrence – A help from yeast quiescent biology and neuronal quiescent cell biologyFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_18_2019 |
7,228 | 5,668 | 12,896 |
Letter to editorLetter to editorFull text![]() ![]() ![]() Year: 2022, Volume: 7, Issue: 2, May – August DOI: 10.25259/IJMIO_10_2022 |
8,352 | 4,471 | 12,823 |
Review ArticleImpact of 2013 ASCO/CAP guidelines on various HER2 reporting categories in breast cancer by fluorescent in-situ hybridization and Immunohistochemistry: A meta-analysis with systematic reviewFull text![]() ![]() ![]() Year: 2020, Volume: 5, Issue: 1, January-April DOI: 10.25259/IJMIO_17_2019 |
6,601 | 6,141 | 12,742 |